stockrowOrganon & Co.
OGNHealthcare Drug Manufacturers General
Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024.
- Revenue
- −1.75%
- EPS
- +1.64%
- Free cash flow
- +118.8%
- Total debt
- −3.10%
Quarter to September 2026, against a year earlier
Follow OGN
Alert me
Organon & Co. (OGN) Operating cash flow
Organon & Co.'s operating cash flow for fiscal 2025 was $700.0M, down 25.5% from $939.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was $843.0M. Over the past ten years it has ranged from $700.0M (fiscal 2025) to $3.7B (fiscal 2018) — the current reading is the lowest in ten years. Organon & Co. ranks 16th of 21 Drug Manufacturers General companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $700.0M | (25.45%) |
| FY2024 | $939.0M | 17.52% |
| FY2023 | $799.0M | (6.88%) |
| FY2022 | $858.0M | (60.28%) |
| FY2021 | $2.2B | (5.43%) |
| FY2020 | $2.3B | (24.37%) |
| FY2019 | $3.0B | (18.09%) |
| FY2018 | $3.7B | 7.84% |
| FY2017 | $3.4B | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $370.0M | 245.79% |
| Jun 2026 | $107.0M | (52.44%) |
| Mar 2026 | $225.0M | 59.57% |
| Dec 2025 | $141.0M | (46.59%) |
| 25 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| SNY Sanofi compare | $23.8B |
| NVO Novo Nordisk A/S compare | $19.2B |
| PFE Pfizer Inc. compare | $14.2B |
| GSK GSK PLC Sponsored ADR compare | $11.8B |
| BMY Bristol Myers Squibb Company compare | $10.7B |
| BIIB Biogen Inc. compare | $2.2B |
| GRFS Grifols, S.A. compare | $1.3B |
| OGN Organon & Co. | $843.0M |
| AMRN Amarin Corporation PLC compare | $37.5M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on OGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement